Search

Your search keyword '"Logothetis C"' showing total 603 results
Start Over Author "Logothetis C"
603 results on '"Logothetis C"'

51. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Pezaro, C J, Omlin, A, Mastris, K, Attard, G, Beer, T M, Chi, K N, Chowdhury, S, Davis, I D, Drake, C G, de Bono, J S, Efstathiou, E, Gravis, G, Higano, C S, Hussain, M, James, N, Logothetis, C J, Morgans, A, Parker, C, Ryan, C J, Saad, F, Sartor, O, Small, E J, Sternberg, C N, Sweeney, C J, Tannock, I, Tombal, Bertrand, Gillessen, S, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Pezaro, C J, Omlin, A, Mastris, K, Attard, G, Beer, T M, Chi, K N, Chowdhury, S, Davis, I D, Drake, C G, de Bono, J S, Efstathiou, E, Gravis, G, Higano, C S, Hussain, M, James, N, Logothetis, C J, Morgans, A, Parker, C, Ryan, C J, Saad, F, Sartor, O, Small, E J, Sternberg, C N, Sweeney, C J, Tannock, I, Tombal, Bertrand, and Gillessen, S

Abstract

The treatment of men with advanced prostate cancer (APC) is changing rapidly, with several new therapeutic options leading to longer survival. Categorizing clinical states that reflect the cancer biology and prior therapy in men with APC has become more complex. The Prostate Cancer Clinical Trials Working Group (PCWG) developed guidelines that harmonized inclusion, monitoring and outcome definitions for clinical trials in APC [1–3]. PCWG2 guidelines were seminal in changing the terminology from ‘hormone-refractory’ or ‘androgen-independent’ to ‘castration-resistant prostate cancer (CRPC)’, based on evidence of men responding to further hormonal manipulations after primary androgen deprivation therapy (ADT). Both of the approved next-generation endocrine agents, abiraterone acetate and enzalutamide, have shown an overall survival benefit for men with progressive cancer despite castrate levels of testosterone [4, 5]. Thus, adopting the term ‘castration-resistant’ improved the biological accuracy of disease characterization compared with ‘hormone refractory’. The term CRPC, although not unanimously accepted, has become embedded in research and clinical practice. [...]

Published
2017

53. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Author

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., Eertwegh, A. J., Krainer, M., Houédé, Nadine, Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F. A., Sundar, S., Agarwal, N., Bergman, A. M., Ciuleanu, T. E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T. M., McHenry, M. B., Gagnier, P., Liu, D., Gerritsen, W. R., Investigators, C. A., Medical oncology, CCA - Innovative therapy, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Département de radiothérapie [Gustave Roussy], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Bergonié [Bordeaux], UNICANCER, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Medical Oncology and Immunotherapy, and Istituto Toscano Tumori-Department. of Oncology-Hospital of Siena

Subjects
Adult, Male, medicine.medical_specialty, Population, Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Docetaxel, Placebo, Gastroenterology, Antibodies, law.invention, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Clinical endpoint, Castration-Resistant/mortality/*therapy, Humans, education, 030304 developmental biology, Aged, 0303 health sciences, education.field_of_study, business.industry, Hazard ratio, Prostatic Neoplasms, Antibodies, Monoclonal, Middle Aged, Combined Modality Therapy, Antineoplastic Agents/*therapeutic use, 3. Good health, Surgery, Prostatic Neoplasms, Castration-Resistant, Oncology, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Disease Progression, Monoclonal/*therapeutic use, Taxoids, business, Taxoids/*therapeutic use, medicine.drug
Abstract

Item does not contain fulltext BACKGROUND: Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy. METHODS: We did a multicentre, randomised, double-blind, phase 3 trial in which men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned in a 1:1 ratio to receive bone-directed radiotherapy (8 Gy in one fraction) followed by either ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Non-progressing patients could continue to receive ipilimumab at 10 mg/kg or placebo as maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death. Patients were randomly assigned to either treatment group via a minimisation algorithm, and stratified by Eastern Cooperative Oncology Group performance status, alkaline phosphatase concentration, haemoglobin concentration, and investigator site. Patients and investigators were masked to treatment allocation. The primary endpoint was overall survival, assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00861614. FINDINGS: From May 26, 2009, to Feb 15, 2012, 799 patients were randomly assigned (399 to ipilimumab and 400 to placebo), all of whom were included in the intention-to-treat analysis. Median overall survival was 11.2 months (95% CI 9.5-12.7) with ipilimumab and 10.0 months (8.3-11.0) with placebo (hazard ratio [HR] 0.85, 0.72-1.00; p=0.053). However, the assessment of the proportional hazards assumption showed that it was violated (p=0.0031). A piecewise hazard model showed that the HR changed over time: the HR for 0-5 months was 1.46 (95% CI 1.10-1.95), for 5-12 months was 0.65 (0.50-0.85), and beyond 12 months was 0.60 (0.43-0.86). The most common grade 3-4 adverse events were immune-related, occurring in 101 (26%) patients in the ipilimumab group and 11 (3%) of patients in the placebo group. The most frequent grade 3-4 adverse events included diarrhoea (64 [16%] of 393 patients in the ipilimumab group vs seven [2%] of 396 in the placebo group), fatigue (40 [11%] vs 35 [9%]), anaemia (40 [10%] vs 43 [11%]), and colitis (18 [5%] vs 0). Four (1%) deaths occurred because of toxic effects of the study drug, all in the ipilimumab group. INTERPRETATION: Although there was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, there were signs of activity with the drug that warrant further investigation. FUNDING: Bristol-Myers Squibb.

Published
2014

54. Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)

Author

Efstathiou, E., primary, Tsikkinis, A., additional, Wen, S., additional, Tapia, E. Li Ning, additional, Hoang, A., additional, Aparicio, A., additional, Tu, S.-M., additional, Rangel, G., additional, Troncoso, P., additional, Corn, P., additional, Araujo, J., additional, and Logothetis, C., additional

Published
2016
Full Text
View/download PDF

55. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties

Author

Paranjape, A N, primary, Soundararajan, R, additional, Werden, S J, additional, Joseph, R, additional, Taube, J H, additional, Liu, H, additional, Rodriguez-Canales, J, additional, Sphyris, N, additional, Wistuba, I, additional, Miura, N, additional, Dhillon, J, additional, Mahajan, N, additional, Mahajan, K, additional, Chang, J T, additional, Ittmann, M, additional, Maity, S N, additional, Logothetis, C, additional, Tang, D G, additional, and Mani, S A, additional

Published
2016
Full Text
View/download PDF

56. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service d'urologie, UCL - (SLuc) Service de radiologie, Gillessen, S, Omlin, A, Attard, G, de Bono, J S, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, P S, Sartor, O, Smith, M R, Soule, H R, Akaza, H, Beer, T M, Beltran, H, Chinnaiyan, A M, Daugaard, G, Davis, I D, De Santis, M, Drake, C G, Eeles, R A, Fanti, S, Gleave, M E, Heidenreich, A, Hussain, M, James, N D, Lecouvet, Frédéric, Logothetis, C J, Mastris, K, Nilsson, S, Oh, W K, Olmos, D, Padhani, A R, Parker, C, Rubin, M A, Schalken, J A, Scher, H I, Sella, A, Shore, N D, Small, E J, Sternberg, C N, Suzuki, H, Sweeney, C J, Tannock, I F, Tombal, Bertrand, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service d'urologie, UCL - (SLuc) Service de radiologie, Gillessen, S, Omlin, A, Attard, G, de Bono, J S, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, P S, Sartor, O, Smith, M R, Soule, H R, Akaza, H, Beer, T M, Beltran, H, Chinnaiyan, A M, Daugaard, G, Davis, I D, De Santis, M, Drake, C G, Eeles, R A, Fanti, S, Gleave, M E, Heidenreich, A, Hussain, M, James, N D, Lecouvet, Frédéric, Logothetis, C J, Mastris, K, Nilsson, S, Oh, W K, Olmos, D, Padhani, A R, Parker, C, Rubin, M A, Schalken, J A, Scher, H I, Sella, A, Shore, N D, Small, E J, Sternberg, C N, Suzuki, H, Sweeney, C J, Tannock, I F, and Tombal, Bertrand

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

Published
2015

57. 826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Author

Sternberg, C.N., Tombal, B., Miller, K., Saad, F., Sartor, O., Sade, J.P., Logothetis, C., Bellmunt, J., Dizdarevic, S., Harshman, L.C., Logue, J., Baldari, S., Richardson, T., Bottomley, D., Schostak, M., Bayh, I., Kalinovsky, J., and Higano, C.

Published
2018
Full Text
View/download PDF

59. Expression of hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signalling

Author

Tzelepi, V. Karlou, M. Wen, S. Hoang, A. Logothetis, C. Troncoso, P. Efstathiou, E.

Abstract

Aims: The hedgehog (Hh) signalling pathway has been implicated in the pathogenesis and aggressiveness of prostate cancer through epithelial-mesenchymal interactions. The aim of this study was to elucidate the cell-type partitioned expression of the Hh pathway biomarkers in the non-neoplastic and tumour microenvironments and to correlate it with the grade and stage of prostate cancer. Methods and results: Expression of the Hh pathway components (Shh, Smo, Ptch, Gli1) in the microenvironment of non-neoplastic peripheral zone (n=119), hormone-naive primary prostate carcinoma (n=141) and castrate-resistant bone marrow metastases (n=53) was analysed using immunohistochemistry in tissue microarrays and bone marrow sections. Results showed that epithelial Shh, Smo and Ptch expression was up-regulated, whereas stromal Smo, Ptch, and Gli1 expression was down-regulated in prostate carcinomas compared to non-neoplastic peripheral zone tissue. Ptch expression was modulated further in high-grade and high-stage primary tumours and in bone marrow metastases. Hh signalling correlated with ki67 and vascular endothelial growth factor (VEGF) but not with CD31 expression. Conclusion: Our results highlight the importance of Hh-mediated epithelial-mesenchymal interactions in the non-neoplastic prostate and imply that shifting the balance from paracrine towards autocrine signalling is important in the pathogenesis and progression of prostate carcinoma. © 2011 Blackwell Publishing Limited.

Published
2011

60. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Author

Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., Eertwegh, A.J. van den, Krainer, M., Houede, N., Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F.A., Sundar, S., Agarwal, N., Bergman, A.M., Ciuleanu, T.E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T.M., McHenry, M.B., Gagnier, P., Liu, D., Gerritsen, W.R., et al., Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., Eertwegh, A.J. van den, Krainer, M., Houede, N., Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F.A., Sundar, S., Agarwal, N., Bergman, A.M., Ciuleanu, T.E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T.M., McHenry, M.B., Gagnier, P., Liu, D., Gerritsen, W.R., and et al.

Abstract

Item does not contain fulltext, BACKGROUND: Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy. METHODS: We did a multicentre, randomised, double-blind, phase 3 trial in which men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned in a 1:1 ratio to receive bone-directed radiotherapy (8 Gy in one fraction) followed by either ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Non-progressing patients could continue to receive ipilimumab at 10 mg/kg or placebo as maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death. Patients were randomly assigned to either treatment group via a minimisation algorithm, and stratified by Eastern Cooperative Oncology Group performance status, alkaline phosphatase concentration, haemoglobin concentration, and investigator site. Patients and investigators were masked to treatment allocation. The primary endpoint was overall survival, assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00861614. FINDINGS: From May 26, 2009, to Feb 15, 2012, 799 patients were randomly assigned (399 to ipilimumab and 400 to placebo), all of whom were included in the intention-to-treat analysis. Median overall survival was 11.2 months (95% CI 9.5-12.7) with ipilimumab and 10.0 months (8.3-11.0) with placebo (hazard ratio [HR] 0.85, 0.72-1.00; p=0.053). However, the assessment of the proportional hazards assumption showed that it was violated (p=0.0031). A piecewise hazard model showed that the HR changed over time: the HR for 0-5 months was 1.46 (95% CI 1.10-1.95), for 5-12 months was 0.65 (0.50-0.85), and beyond 12 months was 0.60 (0.43-0.86).

Published
2014

61. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research

Author

Kantoff, P., Morris, M.J., George, D., Wilding, G., Carducci, M.A., Basch, E.M., Slovin, S.E., Small, E.J., Oh, W.K., Mathew, P., Logothetis, C., Hussain, M., Ryan, C., Higano, C., Beer, T.M., and Scher, H.I.

Subjects
humanities
Abstract

Background: In 2005, the US Department of Defense, through the US Army Medical Research and Materiel Command, Office of the Congressionally Directed Medical Research Programs, created a funding mechanism to form a clinical trials consortium to conduct phase I and II studies in prostate cancer. This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC). Patients and Methods: The Department of Defense award supports a consortium of 10 prostate cancer research centers. Memorial Sloan-Kettering Cancer Center was awarded the Coordinating Center grant for the consortium and charged with creating an infrastructure to conduct early-phase multicenter clinical trials. Each participating center was required to introduce ≥ 1 clinical trial per year and maintain accrual of a minimum of 35 patients per year. Results: The PCCTC was launched in 2006 and now encompasses 10 leading prostate cancer research centers. Fifty-one trials have been opened, and 1386 patients have been accrued at member sites. Members share an online clinical trial management system for protocol tracking, electronic data capture, and data storage. A legal framework has been instituted, and standard operating procedures, an administrative structure, editorial support, centralized budgeting, and mechanisms for scientific review are established. Conclusion: The PCCTC fulfills a congressional directive to create a clinical trials instrument dedicated to early-phase prostate cancer studies. The member institutions have built an administrative, informatics, legal, financial, statistical, and scientific infrastructure to support this endeavor. Clinical trials are open and accruing in excess of federally mandated goals.

Published
2009
Full Text
View/download PDF

62. Maximal Androgen Depletion with Abiraterone Acetate (Aa) Followed By Randomization of Maximal Androgen Ablation with Molecular Targeted Therapies Dasatinib or Sunitinib Malate in Metastatic Castrate Resistant Prostate Cancer (Mcrpc). Report on Candidate Predictive Androgen Signaling Signature

Author

Efstathiou, E., primary, Li Ning Tapia, E., additional, Aparicio, A., additional, Tu, S.M., additional, Wen, S., additional, Hoang, A., additional, Pagliaro, L., additional, Harmon, C., additional, Troncoso, P., additional, Araujo, J.C., additional, and Logothetis, C., additional

Published
2014
Full Text
View/download PDF

63. Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Author

Fizazi, K., primary, Drake, C.G., additional, Kwon, E.D., additional, Bossi, A., additional, van den Eertwegh, A.J., additional, Scher, H.I., additional, Beer, T.M., additional, McHenry, M.B., additional, Liu, D., additional, Gerritsen, W.R., additional, and Logothetis, C., additional

Published
2014
Full Text
View/download PDF

69. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

Author

Scher, H. I., primary, Heller, G., additional, Molina, A., additional, Kheoh, T. S., additional, Attard, G., additional, Moreira, J., additional, Sandhu, S. K., additional, Parker, C., additional, Logothetis, C., additional, McCormack, R. T., additional, Fizazi, K., additional, Anand, A., additional, Danila, D. C., additional, Fleisher, M., additional, Olmos, D., additional, Haqq, C. M., additional, and De Bono, J. S., additional

Published
2011
Full Text
View/download PDF

70. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.

Author

Logothetis, C., primary, De Bono, J. S., additional, Molina, A., additional, Basch, E. M., additional, Fizazi, K., additional, North, S. A., additional, Chi, K. N., additional, Jones, R. J., additional, Goodman, O. B., additional, Mainwaring, P. N., additional, Sternberg, C. N., additional, Gagnon, D. D., additional, Dhawan, R., additional, Rothman, M., additional, Hao, Y., additional, Liu, C. S., additional, Kheoh, T. S., additional, Scher, H. I., additional, and Haqq, C. M., additional

Published
2011
Full Text
View/download PDF

74. Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).

Author

Beer, T. M., primary, Logothetis, C., additional, Sharma, P., additional, Gerritsen, W. R., additional, Ezzeddine, R., additional, Fairchild, J. P., additional, Gagnier, P., additional, Chin, K. M., additional, and Cuillerot, J., additional

Published
2011
Full Text
View/download PDF

77. Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy.

Author

Scher, H. I., primary, Logothetis, C., additional, Molina, A., additional, Goodman, O. B., additional, Sternberg, C. N., additional, Chi, K. N., additional, Kheoh, T. S., additional, Haqq, C. M., additional, Fizazi, K., additional, and De Bono, J. S., additional

Published
2011
Full Text
View/download PDF

84. On Unique Estimation of Azimuth-Elevation-Carriers by Volume Arrays

Author

UPPSALA UNIV (SWEDEN) SIGNALS AND SYSTEMS GROUP, Urazghildiiev, I., Logothetis, C. C., Rydberg, A., Wallin, K., UPPSALA UNIV (SWEDEN) SIGNALS AND SYSTEMS GROUP, Urazghildiiev, I., Logothetis, C. C., Rydberg, A., and Wallin, K.

Abstract

The necessary and sufficient conditions in terms of antenna array geometry for unique estimation of azimuth-elevation-carriers (AEC) of narrow-band signals are introduced. These conditions make it possible to solve the problem of joint AEC estimation based on spatial samples taken by the volume array without using the large number of temporal samples., Presented at International Conference on Mathematical Methods in Electromagnetic Theory (9th) held in Kiev, Ukraine on 10-13 Sep 2002. This article is from ADA413455 2002 International Conference on Mathematical Methods in Electromagnetic Theory (MMET 02). Volume 2

Published
2002

91. Immunologic impact of anti-CTLA-4 therapy

Author

Sharma, P., primary, Tsavachidou, D., additional, Kamat, A., additional, Ng Tang, D., additional, Chen, H., additional, Fu, T., additional, Troncoso, P., additional, Wolchok, J., additional, Logothetis, C. J., additional, and Allison, J. P., additional

Published
2009
Full Text
View/download PDF

94. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

Author

Mathew, P, primary, Thall, P F, additional, Wen, S, additional, Bucana, C, additional, Jones, D, additional, Horne, E, additional, Oh, W K, additional, Morris, M J, additional, Lee, Y-C, additional, Logothetis, C J, additional, Lin, S-H, additional, and Fidler, I J, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results